Navigation

Investiment.io
Financial analysis platform

Eli Lilly and Company

LLY • NYSE

$1,431.67
▼11.83 (0.82%)• REGULAR

Eli Lilly and Company

$1,431.67
▼0.8%
📊Summary📋SEC Filings👥Insider Trading
📄

LLY Q2 2020 Earnings Call

July 30, 2020 at 12:00 AM

Company
LLY
Quarter
Q2 2020
Date
July 30, 2020 at 12:00 AM
Speakers
2
Word Count
~2,911

Transcript Content

Speaker
Thanks Josh. Since our last call, we’ve had major lifecycle readouts for three of our most important new medicines; Verzenio, Trulicity, and Jardiance. All three were positive, all represent clinically meaningful advances for patients, and all should help drive continued growth for these important brands. I’ll speak briefly about each, as well as the Phase 3 readout from Mirikizumab, a molecule still under development. In addition to advancing our existing R&D portfolio, we have devoted significant efforts to creating and testing potential therapies for COVID-19 and here too we have made good progress this quarter. Before I go through the pipeline update, I'll provide an overview of the active programs we are pursuing to treat or prevent COVID-19. These programs have moved with unprecedented speed in hopes of finding new medicine to help blunt the impact of the virus. Baricitinib, our JAK inhibitor, has two ongoing Phase 3 clinical trials in patients hospitalized with COVID-19. The anti-inflammatory activity observed by Baricitinib in other diseases is thought to be potentially beneficial in treating COVID-19. The first trial is investigating Baricitinib in combination with Remdesivir as part of the NIAID’s Adaptive COVID-19 Treatment Trial, and we expect to have data from this trial within the coming months. The second trial is Lilly sponsored and is assessing Baricitinib as monotherapy. We expect results from this trial later this year. Second, we are pursuing a Phase 2 trial of an antibody that targets Angiopoietin 2, which has been observed to be elevated in patients with acute respiratory distress syndrome or ARDS. Based on trial enrollment, we now expect to have data in-house this fall to inform next steps. While these two efforts may inform treatment of symptoms of COVID-19, the approach I’m most excited about is virus neutralizing antibodies for the treatment and prevention of COVID-19, both single antibody therapies and in combinations. We currently have efforts ongoing with LY-CoV555, which arose from our collaboration with AbCellera, and with LY-CoV016, which we licensed from Junshi Biosciences. The development status is summarized on slide 15. Both antibodies have completed dosing in their Phase 1 studies with safety and PK results that support advancing the molecules. Neither Phase 1 study was designed to collect efficacy data; that is, the LY-CoV555 trial only enrolled six patients per dose and LY-CoV016 enrolled only healthy volunteers. LY-CoV555 is further along in development and has progressed to a large dose-ranging Phase 2 study in ambulatory patients recently diagnosed with COVID-19. Here we are focused on reducing viral load. The study is enrolling quickly, and we should have data to report by Q4. This will be our first opportunity to share human efficacy data from the neutralizing antibody program. Based on safety and tolerability data gathered to date, as well as taking into account the gravity of the unmet medical need here, we plan to initiate registrational studies in the coming weeks, even in advance of having efficacy data. We've been in studies across several different patient populations, including a Phase 3 study for prevention of COVID-19 in residents and staff at long-term care facilities, as well as additional registrational studies for potential treatment indication in both the ambulatory and hospitalized settings. Once underway, the timing for data disclosure from these trials will be highly dependent on patient enrollment and any interim efficacy and safety data we may see. In addition to the monotherapy trials I describe for LY-CoV555, we intend to test the combination of LY-CoV016 with LY-CoV555, in case such a combination is needed to combat viral resistance. We look forward to producing additional data for both programs and we’ll provide updates as we achieve program milestones or data become available. We continue to invest in manufacturing for these potential therapies at risk and we are focused on ramping up our manufacturing capacity as quickly as possible. While developing treatments for COVID-19 is an important priority for Lilly right now, we also continue to advance the rest of our pipeline to help people with diabetes, immune disorders, neurodegeneration, and cancer. One particularly exciting development this quarter was the positive interim readout of the MonarchE trial, assessing the use of Verzenio to reduce the risk of recurrence in HR-positive, HER2-negative high-risk early breast cancer. Verzenio is the only CDK4/6 inhibitor to show a benefit in this setting, where another competing product failed at our T-cell analysis. Our conviction and the differentiation of Verzenio from the competition continues to increase based on important data, including safety and tolerability data and mechanism of action that have allowed for continuous dosing and therefore continuous target inhibition. This is a unique feature of Abemaciclib. Clinical efficacy that supports use even as a monotherapy in metastatic breast cancer, another unique feature of Abemaciclib. The demonstrated benefit in overall survival in the metastatic setting in combination with Fulvestrant, something not all CDK4/6 inhibitors have been able to show, and most recently, positive results in the adjuvant setting, another unique feature of Abemaciclib. These data continue to support our convictions, but not all CDK4/6 inhibitors are the same. The positive results in MonarchE could significantly increase the opportunity for Verzenio. Looking at the MonarchE study clinical pathological criteria for enrollment, we estimate that approximately 20,000 patients in the U.S. would match these criteria. This represents a roughly 50% increase over the current addressable market in metastatic breast cancer. Our market is projected to reach almost $7 billion in 2020. In addition, we anticipate the duration of therapy in the adjuvant setting will be longer. We plan to submit this data by the end of the year to regulators around the world and to present them at a major medical meeting in 2020. Kevin Hern (Head of Investor Relations): Thank you, Dan. Josh, can you please provide additional insights on our financial results and guidance? Thank you, Dave. We’d like to take questions from as many callers as possible, so we ask that you limit your questions to two per caller. Kevin, if you can please provide the instructions for the Q&A session and then we're ready for the first caller.
Operator
We will now go to the first question from Seamus Fernandez at Guggenheim. One moment please. Your line is now open.
Speaker
Yeah, can you hear me? Kevin Hern (Head of Investor Relations): Yes, yes.